Bristol-Myers Squibb Company
$ 61.60
0.57%
24 Feb - close price
- Market Cap 125,446,775,000 USD
- Current Price $ 61.60
- High / Low $ 61.91 / 61.01
- Stock P/E 17.80
- Book Value 9.07
- EPS 3.46
- Next Earning Report 2026-04-30
- Dividend Per Share $2.49
- Dividend Yield 4.07 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.40 %
- 52 Week High 62.05
- 52 Week Low 41.88
About
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Analyst Target Price
$61.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-10-30 | 2025-07-31 | 2025-04-24 | 2025-02-06 | 2024-10-31 | 2024-07-26 | 2024-04-25 | 2024-02-02 | 2023-10-26 | 2023-07-27 | 2023-04-27 |
| Reported EPS | 1.26 | 1.63 | 1.46 | 1.8 | 1.67 | 1.8 | 2.07 | -4.4 | 1.59 | 2 | 1.75 | 2.05 |
| Estimated EPS | 1.63 | 1.69 | 1.1 | 1.5 | 1.47 | 1.5 | 1.63 | -4.14 | 1.43 | 1.76 | 1.98 | 1.97 |
| Surprise | -0.37 | -0.06 | 0.36 | 0.3 | 0.2 | 0.3 | 0.44 | -0.26 | 0.16 | 0.24 | -0.23 | 0.08 |
| Surprise Percentage | -22.6994% | -3.5503% | 32.7273% | 20% | 13.6054% | 20% | 26.9939% | -6.2802% | 11.1888% | 13.6364% | -11.6162% | 4.0609% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.44 |
| Currency | USD |
Previous Dividend Records
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-02-02 | 2025-11-03 | 2025-08-01 | 2025-05-01 | 2025-02-03 | 2024-11-01 | 2024-08-01 | 2024-05-01 | 2024-02-01 | 2023-11-01 |
| Amount | $0.63 | $0.62 | $0.62 | $0.62 | $0.62 | $0.6 | $0.6 | $0.6 | $0.6 | $0.57 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BMY
2026-02-24 22:24:00
Viatris (NASDAQ:VTRS) is set to announce its Q4 earnings results before market hours tomorrow. The market expects the company's revenue to be flat year-on-year, following a strong last quarter where Viatris beat revenue expectations. Although the pharmaceuticals segment has generally underperformed, Viatris's stock is up 21.5% over the last month, heading into earnings with an average analyst price target of $14.11.
2026-02-24 16:52:41
Lantheus Holdings Inc. (NASDAQ: LNTH) has experienced a significant stock selloff, leading investors to question if it's a breakout setup or a value trap. The company, focused on specialized US imaging and diagnostics, has seen high volatility due to earnings commentary, guidance updates, and broader market shifts in biotech. Analysts generally maintain positive ratings, with discussions centering on growth quality versus concentration risk, valuation compared to peers, and the potential of its pipeline and partnerships.
2026-02-24 13:37:49
Bristol Myers Squibb recently achieved positive Phase 2 results for Reblozyl in alpha-thalassemia and secured FDA Priority Review for iberdomide in multiple myeloma. These developments are crucial as they bolster the company's newer oncology and hematology assets, aiming to offset future patent expiries of drugs like Eliquis and Opdivo. While these successes strengthen the near-term outlook, investors should also consider the company's rising leverage and large past buybacks.
2026-02-24 12:51:55
Kyverna Therapeutics has appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors, with Emany taking on the role of Audit Committee Chair. These appointments are expected to bolster Kyverna's financial strategy, capital markets expertise, clinical development, and product approval experience as the company advances its autoimmune CAR T programs toward commercialization. Dr. Miller is notably the founder and former President of R&D at Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion.
2026-02-24 11:51:49
First Financial Bankshares Inc has increased its stake in Merck & Co., Inc. by 1.9%, now holding 721,010 shares valued at approximately $60.5 million. This reflects a broader trend of institutional investment in Merck, with such investors owning about 76% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for Merck, anticipating a target price of around $124.80, despite long-term concerns regarding Keytruda's patent expiration around 2028.
2026-02-24 08:08:49
The FDA has accepted Bristol Myers Squibb's New Drug Application (NDA) for iberdomide, an investigational treatment for relapsed or refractory multiple myeloma (RRMM). The application received Priority Review and Breakthrough Therapy Designation, with a target action date of August 17, 2026. Iberdomide, a potential first-in-class oral medicine, utilizes targeted protein degradation and aims to provide an effective treatment option indicated by its ability to achieve Minimal Residual Disease (MRD) negativity.
